Filed: 8/7/2024ACC: 0000950123-24-007328
📋 What this filing means
VERSANT VENTURE MANAGEMENT, LLC filed this quarterly 13F‑HR report disclosing 8 equity positions with a total reported market value of $77.30M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
8
Positions
$77.30M
Total AUM (reported)
15.62M
Total Shares
Allocation by class
COMMON STOCK$50.37M65.2%
COMMON SHARES$26.93M34.8%
Portfolio Concentration
Top 3$59.18M76.6%
4–10$18.12M23.4%
Top 3 weight
76.6%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 15.62M
Sole
Full voting authority
0.00
shares
% of voting shares0.0%
Shared
Joint voting authority
15.62M
shares
% of voting shares100.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole0
Shared0
Other8
Dominant voting typeShared · 100.0% of voting shares
Institutional Holdings8
Rows:
CRISPR Therapeutics AG
OTRShares498.56K
TypeSH
Market value$26.93M
34.84%
Sole
0.00
Shared
498.56K
None
0.00
Contineum Therapeutics, Inc.
OTRShares918.16K
TypeSH
Market value$16.17M
20.92%
Sole
0.00
Shared
918.16K
None
0.00
Skye Bioscience, Inc.
OTRShares2.01M
TypeSH
Market value$16.08M
20.81%
Sole
0.00
Shared
2.01M
None
0.00
Repare Therapeutics, Inc.
OTRShares2.65M
TypeSH
Market value$8.73M
11.30%
Sole
0.00
Shared
2.65M
None
0.00
Adverum Biotechnologies, Inc.
OTRShares506.82K
TypeSH
Market value$3.48M
4.50%
Sole
0.00
Shared
506.82K
None
0.00
Passage Bio, Inc.
OTRShares4.03M
TypeSH
Market value$3.20M
4.14%
Sole
0.00
Shared
4.03M
None
0.00
Gritstone Oncology, Inc.
OTRShares3.56M
TypeSH
Market value$2.20M
2.85%
Sole
0.00
Shared
3.56M
None
0.00
Aligos Therapeutics, Inc.
OTRShares1.46M
TypeSH
Market value$510.3K
0.66%
Sole
0.00
Shared
1.46M
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
CRISPR Therapeutics AGOTR | Common Shares | 498.56K | SH | $26.93M 34.84% | 0.00 | 498.56K | 0.00 |
Contineum Therapeutics, Inc.OTR | Common Stock | 918.16K | SH | $16.17M 20.92% | 0.00 | 918.16K | 0.00 |
Skye Bioscience, Inc.OTR | Common Stock | 2.01M | SH | $16.08M 20.81% | 0.00 | 2.01M | 0.00 |
Repare Therapeutics, Inc.OTR | Common Stock | 2.65M | SH | $8.73M 11.30% | 0.00 | 2.65M | 0.00 |
Adverum Biotechnologies, Inc.OTR | Common Stock | 506.82K | SH | $3.48M 4.50% | 0.00 | 506.82K | 0.00 |
Passage Bio, Inc.OTR | Common Stock | 4.03M | SH | $3.20M 4.14% | 0.00 | 4.03M | 0.00 |
Gritstone Oncology, Inc.OTR | Common Stock | 3.56M | SH | $2.20M 2.85% | 0.00 | 3.56M | 0.00 |
Aligos Therapeutics, Inc.OTR | Common Stock | 1.46M | SH | $510.3K 0.66% | 0.00 | 1.46M | 0.00 |